160 related articles for article (PubMed ID: 32845986)
1. The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma.
Callaghan CM; Seyedin SN; Mohiuddin IH; Hawkes KL; Petronek MS; Anderson CM; Buatti JM; Milhem MM; Monga V; Allen BG
Radiat Res; 2020 Aug; 194(2):124-132. PubMed ID: 32845986
[TBL] [Abstract][Full Text] [Related]
2. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Luke JJ; Lemons JM; Karrison TG; Pitroda SP; Melotek JM; Zha Y; Al-Hallaq HA; Arina A; Khodarev NN; Janisch L; Chang P; Patel JD; Fleming GF; Moroney J; Sharma MR; White JR; Ratain MJ; Gajewski TF; Weichselbaum RR; Chmura SJ
J Clin Oncol; 2018 Jun; 36(16):1611-1618. PubMed ID: 29437535
[TBL] [Abstract][Full Text] [Related]
3. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for metastatic sarcoma to the lung: adding to the arsenal of local therapy.
Gutkin PM; Gore E; Charlson J; Neilson JC; Johnstone C; King DM; Hackbarth DA; Wooldridge A; Mannem R; Bedi M
Radiat Oncol; 2023 Mar; 18(1):42. PubMed ID: 36859309
[TBL] [Abstract][Full Text] [Related]
5. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
7. Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma.
Parsai S; Sedor G; Smile TD; Scott J; Ochocki A; Vassil N; Zahler S; Angelov L; Chao ST; Qi P; Anderson P; Murphy ES
Am J Clin Oncol; 2021 Mar; 44(3):126-130. PubMed ID: 33405479
[TBL] [Abstract][Full Text] [Related]
8. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
Xie G; Gu D; Zhang L; Chen S; Wu D
Cancer Biol Ther; 2017 Aug; 18(8):547-551. PubMed ID: 28665741
[TBL] [Abstract][Full Text] [Related]
9. Multi-institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity.
Baumann BC; Bernstein KA; DeLaney TF; Simone CB; Kolker JD; Choy E; Levin WP; Weber KL; Muniappan A; Berman AT; Staddon A; Hartner L; Van Tine B; Hirbe A; Glatstein E; Hahn SM; Nagda SN; Chen YL
J Surg Oncol; 2020 Oct; 122(5):877-883. PubMed ID: 32588468
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
13. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM; Antonescu CR; Bowler T; Munhoz R; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Dholakia R; Ahmad H; Biniakewitz M; Condy M; Phelan H; Callahan M; Wong P; Singer S; Ariyan C; Bartlett EK; Crago A; Yoon S; Hwang S; Erinjeri JP; Qin LX; Tap WD; D'Angelo SP
JAMA Oncol; 2020 Mar; 6(3):402-408. PubMed ID: 31971541
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.
Baumann BC; Nagda SN; Kolker JD; Levin WP; Weber KL; Berman AT; Staddon A; Hartner L; Hahn SM; Glatstein E; Simone CB
J Surg Oncol; 2016 Jul; 114(1):65-9. PubMed ID: 27111504
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.
Feng XY; Li J; Li AM; Jing SH; Zhu XX; Wang Z
World J Surg Oncol; 2022 Sep; 20(1):322. PubMed ID: 36171617
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.
Harris JP; Park J; Ku E; Seyedin S; Stitzlein R; Goldin A; Chen WP; McLaren C; Chen AM; Chow W
Cancer Control; 2024; 31():10732748241237331. PubMed ID: 38449377
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
19. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC; Polley MY; Bhave SR; Redler G; Pitroda SP; Luke JJ; Chmura SJ
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):189-195. PubMed ID: 32569799
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.
Loi M; Duijm M; Baker S; Rossi L; Grunhagen D; Verhoef C; Nuyttens J
Radiol Med; 2018 Nov; 123(11):871-878. PubMed ID: 29923086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
